(Q38154289)

29 August 2017

title

Immunotherapy for lung cancer: ongoing clinical trials (English)

1 reference

29 August 2017

1 reference

1 reference

Sarah Declerck

1

1 reference

29 August 2017

Johan Vansteenkiste

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

22 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

91-105

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Lung cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

MUC1 immunobiology: from discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Functions of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

N-Glycolylneuraminic acid in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Facilitation of fiberoptic nasotracheal intubation in a morbidly obese patient by simultaneous use of nasal CPAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Combining radiotherapy and cancer immunotherapy: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.166

21 January 2018

Identifiers

DOI

10.2217/FON.13.166

1 reference

29 August 2017

1 reference